These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

974 related items for PubMed ID: 15239086

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
    Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, Finucci GF, Casiglia E, Sticca A, De Toni R, Pavan L, Gatta A.
    Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
    Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A.
    Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
    Wong F, Raina N, Richardson R.
    Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems.
    Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, Garcia-Pagan JC, Bosch J, Arroyo V, Rodés J.
    Hepatology; 1998 Aug; 28(2):416-22. PubMed ID: 9696006
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study.
    Tandon P, Tsuyuki RT, Mitchell L, Hoskinson M, Ma MM, Wong WW, Mason AL, Gutfreund K, Bain VG.
    Liver Int; 2009 Feb; 29(2):169-74. PubMed ID: 18492024
    [Abstract] [Full Text] [Related]

  • 12. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function.
    Somberg KA, Lake JR, Tomlanovich SJ, LaBerge JM, Feldstein V, Bass NM.
    Hepatology; 1995 Mar; 21(3):709-16. PubMed ID: 7875668
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin.
    Rice JP, Skagen C, Said A.
    Transplantation; 2011 May 27; 91(10):1141-7. PubMed ID: 21544034
    [Abstract] [Full Text] [Related]

  • 20. Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial.
    Umgelter A, Reindl W, Wagner KS, Franzen M, Stock K, Schmid RM, Huber W.
    Crit Care; 2008 May 27; 12(1):R4. PubMed ID: 18197961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.